Abstract:Introduction Dilated cardiomyopathy (DCM) exhibits an annual incidence of 5-7 cases per 100,000 persons and a worldwide prevalence of 1:2500 individuals, with a genetic involvement in 35% of all cases (TTN and LMNA gene mutation accounting for the majority). Amongst the numerous genetic mutations, prior research has linked PTPN11 gene mutations to hypertrophic cardiomyopathy. Our case sheds light on the association between PTPN11 mutation and the development of isolated DCM. Case A 54-year-old lady with no remarkable medical history presented with typical symptoms of heart failure. CT coronary angiography revealed normal coronary arteries, and echocardiography (fig.1) demonstrated a left ventricular ejection fraction of 40%, with an indexed left ventricular end-diastolic volume (LVEDVi) of 79 ml/m2, suggestive of moderate-severe dilation. The patient also had a family history of non-ischemic heart failure with reduced ejection fraction (HFrEF) in her younger sister at the age of 45, reportedly due to stress but with no extensive workup. Stemming from the patient's refusal to undergo cardiac MRI, genetic testing was pursued, and she underwent whole genome testing which identified a missense mutation in coding exon 7 of the PTPN11 gene. Discussion PTPN11 is a gene that produces SHP2, a tyrosine phosphatase (PTP) protein. A gain of function mutation in PTPN11 is responsible for approximately 50% of cases of Noonan syndrome (NS). Although NS is commonly associated with hypertrophic cardiomyopathy (HCM) that leads to heart failure with preserved ejection fraction (HFpEF), the prevalence of HCM is low in individuals with NS caused by PTPN11 mutation. Conversely, DCM, which leads to HFrEF, has been rarely reported in NS, with only two documented cases in literature, albeit correlation with PTPN11 was not specified. Murine studies suggested that a deletion mutation in PTPN11 leads to abnormal activation of the Erk/MAPK protein and RhoA signaling pathways, resulting in rapid DCM development. Additionally, missense defects in PTPN11 were found to lead to prolonged phosphatase activity, mutations of which (mainly PP1 and PP2A, reportedly present in human hearts) also lead to DCM. Our patient was found to carry a specific PTPN11 mutation: c.794G>T(p.Arg265Leu), which is inherited in an autosomal dominant manner. Given that she had no predisposing factors for DCM, it is speculated that this PTPN11 variant may be an independent risk factor for isolated DCM induced HFrEF. Further clinical correlation and familial testing are required to fully understand the effect of this variant on the heart, which could have significant implications for both diagnosis and treatment of this debilitating cardiovascular disorder.

A hidden cause of middle-aged onset heart failure with preserved ejection fraction: a GTPBP3 variant

The Novel Mitochondrial 16S Rrna 2336T>C Mutation is Associated with Hypertrophic Cardiomyopathy

Inhibition of HSC70 Alleviates Hypertrophic Cardiomyopathy Pathology in Human Induced Pluripotent Stem Cell‐derived Cardiomyocytes with a MYBPC3 Mutation

Mitochondrial Transfer RNAMet 4435A>G Mutation is Associated with Maternally Inherited Hypertension in a Chinese Pedigree.

Failures in Mitochondrial Trnamet and Trnagln Metabolism Caused by the Novel 4401A>G Mutation Are Involved in Essential Hypertension in a Han Chinese Family.

Deletion of Gtpbp3 in zebrafish revealed the hypertrophic cardiomyopathy manifested by aberrant mitochondrial tRNA metabolism

Mitochondrial Dysfunctions Contribute to Hypertrophic Cardiomyopathy in Patient Ipsc-Derived Cardiomyocytes with MT-RNR2 Mutation.

Mitochondrial Dysfunction Caused by M.2336t > C Mutation with Hypertrophic Cardiomyopathy in Cybrid Cell Lines

Mutations in GTPBP3 cause a mitochondrial translation defect associated with hypertrophic cardiomyopathy, lactic acidosis, and encephalopathy

PTPN11 Mutation, A Heartbreaking Revelation

Glycogen storage disease with massive left ventricular hypertrophy and increased native T1: a case report

Defects in the mitochondrial-tRNA modification enzymes MTO1 and GTPBP3 promote different metabolic reprogramming through a HIF-PPARγ-UCP2-AMPK axis

A pathogenic nonsense mutation (c.1522C>T) of the MYBPC3 gene is implicated with hypertrophic cardiomyopathy

An analysis of mitochondrial variation in cardiomyopathy patients from the 100,000 genomes cohort: m.4300A>G as a cause of genetically elusive hypertrophic cardiomyopathy

A human mitofusin 2 mutation can cause mitophagic cardiomyopathy

Renal and cardiac biopsy findings in an adolescent patient with the 3243A>G mitochondrial DNA mutation: Favorable renal prognosis post renal transplantation from the mother

Identification of novel TTN gene variant in a patient exhibiting severe dilated cardiomyopathy co-occurring with acute fibrinoid organizing pneumonia

Whole-exome Sequencing Reveals a Novel Mutation of MT-ND5 Gene in a Mitochondrial Cardiomyopathy Pedigree: Patients Who Show Biventricular Hypertrophy, Hyperlactacidemia, Pulmonary Hypertension, and Decreased Exercise Tolerance.

Identification and Functional Characterization of Mutations Within HADHB Associated with Mitochondrial Trifunctional Protein Deficiency.

Novel Mutations in the GTPBP3 Gene for Mitochondrial Disease and Characteristics of Related Phenotypic Spectrum: The First Three Cases From China

P.232Hereditary myopathy with early respiratory failure in Chinese population